Cell Therapy Manufacturing And Economies Of Scale
During our second Cell & Gene Live – Can Innovation Drive Down Cell Therapy Manufacturing Costs? – panelists Dr. Mark Gilbert, SVP of R&D of Acepodia; Thomas Lequertier, Head of Cell Therapy Manufacturing Unit of Celyad Oncology; and Ludek Sojka, Ph.D., Chief Technology Officer of SOTIO discussed how both allogeneic and autologous therapies alike are affected by the high cost of manufacturing. Indeed, the high cost of producing new cell therapies, particularly gene-edited cell therapies such as CAR T-cell therapy, for example, are notoriously expensive. Advancements in manufacturing are driving costs down, but not at the required pace. The complex manufacturing process that these biological treatments require means that their price is currently at a premium.
In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Ludek Sojka discussed why autologous and allogeneic therapies are, in fact, scalable as well as the hurdles and wins associated with achieving scalability.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.